Axcella Health (AXLA) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Axcella Reports Second Quarter Financial Results and Provides Business Update
July 29, 2021 7:28 AM EDTInitiated EMMPOWER Phase 2 clinical trial of AXA1665 for the reduction in risk of recurrent OHE Initiated EMMPACT Phase 2b clinical trial of AXA1125 for the treatment of NASH Presented data at key medical congresses Enhanced management team with the addition of Chief People Officer Company to host conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic... More
